Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	156-57-0
Formula :	C₂H₈ClNS
M.W :	113.61
SMILES Code :	NCCS.[H]Cl
Synonyms :	2-Aminoethanethiol hydrochloride; 2-Mercaptoethylamine hydrochloride; β-Mercaptoethylamine
MDL No. :	MFCD00012904
InChI Key :	OGMADIBCHLQMIP-UHFFFAOYSA-N
Pubchem ID :	9082

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H317-H335
Precautionary Statements:	P501-P261-P272-P270-P271-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P333+P313-P301+P312+P330-P304+P340+P312-P403+P233-P405

Pseudomonas aeruginosa DgcvP2 mutant	200 mg/L	24 hours	Cysteamine inhibited glycine utilization by P. aeruginosa DgcvP2 mutant	PMC8494450
Pseudomonas aeruginosa PAO1	200 mg/L	24 hours	Cysteamine inhibited glycine utilization by P. aeruginosa PAO1	PMC8494450
Gilthead sea bream (Sparus aurata) myocytes	200 µM	4 days	To evaluate cell viability and GH/IGF axis-related gene expression. Results showed that CSH treatment increased cell viability and upregulated mRNA levels of ghr1, igf-1b, igf-2, and igf-1rb compared to the control group.	PMC10400459
Calu-3 cells	500-125 μM	48 hours	To assess the impact of cysteamine and cystamine on SARS-CoV-2 replication. Results demonstrated that both compounds significantly reduced viral production.	PMC8750154
THP-1 cells	800 µM	48 hours	Restricted intracellular replication compared to the untreated control	PMC9866335
THP-1 cells	400 µM	48 hours	Restricted intracellular replication compared to the untreated control	PMC9866335
Burkholderia cepacia complex (BCC) clinical isolates and type strains	128 μg/ml	48 hours	To assess the utility of cysteamine as an adjunct antibiotic therapy against BCC in vitro, results showed that cysteamine potentiated the activity of tobramycin, ciprofloxacin, and trimethoprim-sulfamethoxazole, reversing resistance in some strains.	PMC5038277
Peripheral blood mononuclear cells (PBMCs)	50-400 µM	6 hours and 24 hours	To evaluate the immunomodulatory effects of cysteamine on Th1 and Tc1 cell responses. Results showed that cysteamine at 400 µM significantly reduced PPD- and SEB-induced Th1 and Tc1 responses.	PMC11550979
Vero E6 cells	500-31.25 μM	72 hours	To evaluate the effect of cysteamine and cystamine on SARS-CoV-2-induced cytopathic effects (CPE). Results showed that both compounds significantly reduced SARS-CoV-2-induced CPE in a dose-dependent manner.	PMC8750154

Gilthead sea bream (Sparus aurata)	Fingerlings (1.8 ± 0.03 g) and juveniles (14.46 ± 0.68 g)	Oral	1.65 g/kg or 3.3 g/kg	9 and 18 weeks	To investigate the effects of CSH on growth performance and the GH/IGF-1 axis. Results showed that CSH-1.65 improved growth performance by 16% and 26.7% after 9 and 18 weeks, respectively, while CSH-3.3 improved 32.3% after 18 weeks. CSH reduced plasma GH levels after 18 weeks and increased IGF-1 levels after 9 and 18 weeks.	PMC10400459
Gilthead sea bream (Sparus aurata)	Fingerlings (1.8 ± 0.03 g) and juveniles (14.46 ± 0.68 g)	Oral	1.65 g/kg or 3.3 g/kg of feed	9 and 18 weeks	To investigate the effects of CSH on growth performance and the GH/IGF-1 axis. Results showed that CSH-1.65 improved growth performance by 16% and 26.7% after 9 and 18 weeks, respectively, while CSH-3.3 improved 32.3% after 18 weeks. CSH reduced plasma GH levels after 18 weeks and increased IGF-1 levels after 9 and 18 weeks.	PMC10400459
Mice	Heterozygous reeler mice (HRM)	Through drinking water	150 mg/kg/day	30 days	To evaluate the potential of cysteamine to improve the deficits in GAD67 expression and cognitive function in HRM. Results showed that cysteamine significantly ameliorated the decreases in GAD67, mature BDNF and full-length TrkB protein levels in frontal cortex and hippocampus of HRM. Additionally, cysteamine improved Y-maze spatial recognition in HRM to the level of wide-type controls and improved PPI in both wild-type and HRM.	PMC3248979
Galleria mellonella	Galleria mellonella larvae infection model	Injection	2, 20, 100, 200 mg/L	Single injection, observed for 48 hours	Cysteamine significantly reduced the toxicity of P. aeruginosa secreted factors	PMC8494450
LDL receptor-deficient mice	High-fat diet-induced atherosclerosis model	Drinking water	2.2 mM (equivalent to 42 mg/kg/day)	Changed daily for 8 weeks	Cysteamine caused regression of atherosclerosis by 32% to 56%, increased markers of plaque stability, reduced liver inflammation and lipid levels, and improved skeletal muscle function.	PMC8649511

{[proInfo.proName]}

CAS No.: 156-57-0

{[proInfo.proName]}

CAS No.: 156-57-0

Alternative Products

Product Details of Cysteamine HCl

Safety of Cysteamine HCl

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00074516	-		Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00006466	Multiple Myeloma and Plasma Ce... More >>ll Neoplasm Precancerous Condition Less <<	Phase 1 Phase 2	Unknown	-	United States, Georgia ... More >> Emory Clinic Atlanta, Georgia, United States, 30322 United States, Maryland Victory Over Cancer Rockville, Maryland, United States, 20852 United States, New York St. Vincents Comprehensive Cancer Center New York, New York, United States, 10011 Less <<
NCT00041379	Lymphoma	Phase 1 Phase 2	Unknown	-	United States, Maryland ... More >> Victory Over Cancer Rockville, Maryland, United States, 20852 Less <<
NCT02304666	Inflammatory Bowel Disease (Cr... More >>ohn's Disease and Ulcerative Colitis) Less <<	Not Applicable	Unknown	October 2018	France ... More >> Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13005 Contact: Jean Charles Grimaud jean-charles.grimaud@ap-hm.fr Less <<
NCT00004312	-		Completed	-	United States, California ... More >> University of California San Diego School of Medicine La Jolla, California, United States, 92093-0652 Less <<
NCT00799578	-		Completed	-	-
NCT00799578	Fatty Liver	Phase 1 Phase 2	Completed	-	United States, California ... More >> University of California, San Diego School of Medicine General Clinic Research Center San Diego, California, United States, 92103-8203 Less <<
NCT02101957	Huntington's Disease	Phase 2 Phase 3	Unknown	-	France ... More >> CHU Angers Angers, France, 49000 Less <<
NCT00007839	Lymphoma	Phase 1 Phase 2	Unknown	-	United States, Maryland ... More >> Victory Over Cancer Rockville, Maryland, United States, 20852 Less <<
NCT00010426	Cystinosis	Not Applicable	Completed	-	-
NCT00002110	HIV Infections	Phase 2	Completed	-	United States, Florida ... More >> Infectious Disease Research Institute Inc Tampa, Florida, United States, 33614 United States, Louisiana Tulane Univ Med School New Orleans, Louisiana, United States, 701122699 United States, New York SUNY / Health Sciences Ctr at Stony Brook Stony Brook, New York, United States, 117948153 United States, North Carolina Bowman Gray School of Medicine / North Carolina Baptist Hosp Winston Salem, North Carolina, United States, 271571042 United States, Rhode Island Independent Research Nurses Inc Cranston, Rhode Island, United States, 02910 United States, Texas Univ of Texas Southwestern Med Ctr of Dallas Dallas, Texas, United States, 75235 Less <<
NCT00028262	-		Completed	-	-
NCT00028262	Infantile Neronal Ceroid Lipof... More >>uscinosis Less <<	Phase 4	Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00359684	-		Recruiting	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov Less <<
NCT01139125	-		Terminated(The study was stopp... More >>ed after 4 years of recruitment difficulties.) Less <<	-	-
NCT01139125	Schizophrenia ... More >> Schizoaffective Less <<	Not Applicable	Terminated(The study was stopp... More >>ed after 4 years of recruitment difficulties.) Less <<	-	United States, Georgia ... More >> Georgia Health Sciences University - Dept of Psychiatry Augusta, Georgia, United States, 30912 Georgia Regents University- Dept of Psychiatry Augusta, Georgia, United States, 30912 Less <<
NCT00001736	Cystinosis	Phase 1	Completed	-	United States, Maryland ... More >> National Eye Institute (NEI) Bethesda, Maryland, United States, 20892 Less <<
NCT00001213	-		Completed	-	-
NCT00715559	-		Terminated(Change in resources... More >> available for study procedures.) Less <<	-	-
NCT03000348	Cystic Fibrosis	Phase 2	Completed	-	United States, Arizona ... More >> Banner University of Arizona Medical Center Tucson, Arizona, United States, 85724 United States, California San Francisco Critical Care Medical Group California Pacific Medical Center San Francisco, California, United States, 94115 United States, Florida University of Florida Gainesville, Florida, United States, 32610 Central Florida Pulmonary Orlando, Florida, United States, 32803 United States, New York Albany Medical College Albany, New York, United States, 12208 United States, Ohio Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 United States, Wisconsin The Medical College of Wisconsin/Froedtert Hospital Milwaukee, Wisconsin, United States, 53226 Italy Ospedale Padiatrico Bambino Gesu Centro Fibrosi Cistica Roma, Italy, 00165 Azienda Ospedaliera Universitaria Integrato di Verona Borgo Trento Centro Fibrosi Cistica Verona, Italy, 37126 United Kingdom Aberdeen Royal Infirmary Aberdeen, Scotland, United Kingdom, AB25 2ZN Ninewells Hospital Scottish Adult Cystic Fibrosis Service Dundee, United Kingdom, DD1 9SY Western General Hospital Edinburgh, CF Adults / CF Unit Edinburgh, United Kingdom, EH4 3HE NHS GGC Glasgow, United Kingdom, G51 4TF Raigmore Hospital Inverness, United Kingdom, IV2 3UJ St. James University Hospital Leeds, United Kingdom, LS9 7TF Royal Victoria Infirmary Adult CF Centre Newcastle upon Tyne, United Kingdom, NE1 4LP Less <<
NCT02766855	Nephropathic Cyctinosis ... More >> Corneal Cystine Crystals Less <<	Not Applicable	Completed	-	-
NCT01000961	Cystinosis	Phase 3	Completed	-	United States, California ... More >> Stanford University Medical School Stanford, California, United States, 94305 United States, Georgia Emory Children's Center Atlanta, Georgia, United States, 30322 United States, Illinois Ann & Robert H. Lurie Children's Hospital of Chicago (formerly Children's Memorial Hospital) Chicago, Illinois, United States, 60614 France Hospices Civils de Lyon Lyon, France Villeneuve-Lapeyronie Hospital Montpellier, France Necker Hospital Paris, France Robert Debre Hospital Paris, France Netherlands Radboud University Nijmegen Medical Center Nijmegen, Netherlands Less <<
NCT00715559	Major Depressive Disorder	Not Applicable	Terminated(Change in resources... More >> available for study procedures.) Less <<	-	United States, New York ... More >> Mount Sinai School of Medicine New York, New York, United States, 10029 Less <<
NCT01529268	Nonalcoholic Fatty Liver Disea... More >>se (NAFLD) Less <<	Phase 2 Phase 3	Completed	-	United States, California ... More >> University of California, San Diego San Diego, California, United States, 92103 University of California, San Francisco San Francisco, California, United States, 94143 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Illinois Ann & Robert H. Lurie Children's Hospital of Chicago (NWU) Chicago, Illinois, United States, 60611-2605 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Missouri St. Louis University Saint Louis, Missouri, United States, 63104 United States, New York Columbia University New York, New York, United States, 10032 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Texas Texas Children's Hospital Houston, Texas, United States, 77030 United States, Washington University of Washington, Seattle Children's Hospital Seattle, Washington, United States, 98105 Less <<
NCT01000961	-		Completed	-	-
NCT00872729	-		Completed	-	-
NCT01529268	-		Completed	-	-
NCT01432561	Cystinosis Ne... More >>phropathic Cystinosis Less <<	Not Applicable	Completed	-	United States, California ... More >> University of California, San Diego Center for Clinical Research Services (CCR) La Jolla, California, United States, 92093 Less <<
NCT00001213	Cystinosis	Phase 2	Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01432561	-		Completed	-	-
NCT00872729	Cystinosis	Phase 1 Phase 2	Completed	-	United States, California ... More >> University of California San Diego Medical Center San Diego, California, United States, 92103 Less <<
NCT02023866	Inherited Mitochondrial Diseas... More >>e, Including Leigh Syndrome Less <<	Phase 2	Completed	-	United States, California ... More >> University of California at San Diego (UCSD) San Diego, California, United States, 92093-0935 Stanford University Stanford, California, United States, 94305 United States, Ohio Akron Children's Hospital Akron, Ohio, United States, 44308 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Utah University of Utah, Division of Medical Genetics Salt Lake City, Utah, United States, 84132 Less <<
NCT01733316	Cystinosis	Phase 3	Completed	-	United States, California ... More >> California Pacific Medical Center (CPMC) Research Institute San Francisco, California, United States, 94115 Stanford University Medical School Stanford, California, United States, 94305 United States, Georgia Emory Children's Center Atlanta, Georgia, United States, 30322 United States, Illinois Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States, 60614 United States, Texas Baylor College of Medicine / Texas Childrens Hospital Houston, Texas, United States, 77030 Belgium University Hospital of Leuven Leuven, Belgium France Hospices Civils de Lyon Lyon, France Hôpital Necker-Enfants Malades Paris, France Hôpital Robert Debré Paris, France Italy Ospedale Pediatrico Bambino Gesù Rome, Italy Netherlands Radboud University Nijmegen Medical Center Nijmegen, Netherlands United Kingdom Queen Elizabeth Hospital Birmingham Birmingham, United Kingdom Great Ormond Street London, United Kingdom Guy's Hospital London, United Kingdom Less <<
NCT02012114	Cystinosis	Not Applicable	Unknown	May 2015	France ... More >> Hospices Civils de Lyon Recruiting Lyon, France, 69002 Less <<
NCT01197378	Cystinosis	Phase 3	Completed	-	United States, California ... More >> California Pacific Medical Center (CPMC) Research Institute San Francisco, California, United States, 94115 Stanford University Medical School Stanford, California, United States, 94305 United States, Georgia Emory Children's Center Atlanta, Georgia, United States, 30322 United States, Illinois Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States, 60614 United States, Texas Texas Children's Hospital/Baylor University Houston, Texas, United States, 77030 France Hospices Civils de Lyon Lyon, France Hôpital Arnaud Villeneuve ‐ CHU Montpellier Montpellier, France Hopital Necker Paris, France Robert Debre Hospital Paris, France Netherlands Radboud University Nijmegen Medical Center Nijmegen, Netherlands Less <<
NCT01197378	-		Completed	-	-
NCT02473445	Mitochondrial Diseases	Phase 2	Terminated(Sponsor decision to... More >> end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.) Less <<	-	United States, California ... More >> University of California at San Diego (UCSD) San Diego, California, United States, 92093-0935 Stanford University School of Medicine Stanford, California, United States, 94305 United States, Ohio Akron Children's Hospital Akron, Ohio, United States, 44308 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 Less <<
NCT01733316	-		Completed	-	-
NCT02473445	-		Terminated(Sponsor decision to... More >> end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.) Less <<	-	-
NCT01744782	Cystinosis	Phase 3	Completed	-	United States, Illinois ... More >> Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States, 60611 Brazil Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo Sao Paulo, SP, Brazil Less <<
NCT02023866	-		Completed	-	-
NCT02212431	Cystic Fibrosis	Phase 1 Phase 2	Completed	-	United Kingdom ... More >> Aberdeen Royal Infirmary Aberdeen, United Kingdom, AB25 2ZN Less <<
NCT01744782	-		Completed	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	8.80mL 1.76mL 0.88mL	44.01mL 8.80mL 4.40mL	88.02mL 17.60mL 8.80mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2 The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed